Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Willemijn J. Comuth"'
Publikováno v:
TH Open, Vol 02, Iss 03, Pp e280-e290 (2018)
Abstract Background The Anti-Clot Treatment Scale (ACTS) is a 17-item, 2-factor (Burdens and Benefits), patient-reported outcome instrument to evaluate patient satisfaction with oral anticoagulant treatment. Objectives This study aimed to transla
Externí odkaz:
https://doaj.org/article/114af848b6cf49b099b55d4e26819ba5
Publikováno v:
TH Open: Companion Journal to Thrombosis and Haemostasis
Comuth, W J, Lauridsen, H H, Kristensen, S D & Münster, A-M B 2018, ' Translation, Cultural Adaptation, and Psychometric Properties of the Danish Version of the Anti-Clot Treatment Scale ', Thrombosis and Haemostasis Open, vol. 2, no. 3, pp. e280-e290 . https://doi.org/10.1055/s-0038-1670631
Comuth, W J, Lauridsen, H H, Kristensen, S D & Münster, A-M B 2018, ' Translation, Cultural Adaptation, and Psychometric Properties of the Danish Version of the Anti-Clot Treatment Scale ', TH Open, vol. 2, no. 3, pp. e280-e290 . https://doi.org/10.1055/s-0038-1670631
TH Open, Vol 02, Iss 03, Pp e280-e290 (2018)
Comuth, W, Lauridsen, H H, Kristensen, S D & Münster, A-M B 2018, ' Translation, cultural adaptation and psychometric properties of the Danish version of the Anti-Clot Treatment Scale. ', Thrombosis and Haemostasis Open, vol. 02, no. 03, pp. e280-e290 . https://doi.org/10.1055/s-0038-1670631
Comuth, W J, Lauridsen, H H, Kristensen, S D & Münster, A-M B 2018, ' Translation, Cultural Adaptation, and Psychometric Properties of the Danish Version of the Anti-Clot Treatment Scale ', Thrombosis and Haemostasis Open, vol. 2, no. 3, pp. e280-e290 . https://doi.org/10.1055/s-0038-1670631
Comuth, W J, Lauridsen, H H, Kristensen, S D & Münster, A-M B 2018, ' Translation, Cultural Adaptation, and Psychometric Properties of the Danish Version of the Anti-Clot Treatment Scale ', TH Open, vol. 2, no. 3, pp. e280-e290 . https://doi.org/10.1055/s-0038-1670631
TH Open, Vol 02, Iss 03, Pp e280-e290 (2018)
Comuth, W, Lauridsen, H H, Kristensen, S D & Münster, A-M B 2018, ' Translation, cultural adaptation and psychometric properties of the Danish version of the Anti-Clot Treatment Scale. ', Thrombosis and Haemostasis Open, vol. 02, no. 03, pp. e280-e290 . https://doi.org/10.1055/s-0038-1670631
Background The Anti-Clot Treatment Scale (ACTS) is a 17-item, 2-factor (Burdens and Benefits), patient-reported outcome instrument to evaluate patient satisfaction with oral anticoagulant treatment.Objectives This study aimed to translate and cultura
Publikováno v:
Comuth, W, Christiansen, J J, Münster, A-M B & Husted, S 2017, ' Bilateral adrenal gland hemorrhage in a patient treated with rivaroxaban ', Blood Coagulation and Fibrinolysis, vol. 28, no. 1, pp. 102–104 . https://doi.org/10.1097/MBC.0000000000000541
This is the report of a case of a 63-year-old woman, with a history of recurrent deep vein thrombosis, who was admitted with abdominal pain and diagnosed with bilateral adrenal hemorrhage, resulting in acute adrenal insufficiency. Several risk factor
Autor:
Willemijn J. Comuth, Moniek P.M. de Maat, Linda Ø Henriksen, Anna-Marie Bloch Münster, Daan van de Kerkhof, Steen Dalby Kristensen, Steen Elkjær Husted
Publikováno v:
Comuth, W J, Henriksen, L Ø, van de Kerkhof, D, Husted, S E, Kristensen, S D, de Maat, M P M & Münster, A-M B 2018, ' Comprehensive characteristics of the anticoagulant activity of dabigatran in relation to its plasma concentration ', Thrombosis Research, vol. 164, pp. 32-39 . https://doi.org/10.1016/j.thromres.2018.02.141
Thrombosis Research, 164, 32-39. Elsevier Ltd.
Thrombosis Research, 164, 32-39. Elsevier
Thrombosis Research, 164, 32-39. Elsevier Ltd.
Thrombosis Research, 164, 32-39. Elsevier
BACKGROUND: Issues with laboratory measurement of dabigatran include: 1. Do coagulation assays reflect dabigatran plasma concentrations? 2. Do samples from patients treated with dabigatran have the same coagulability as dabigatran-spiked samples from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dec6e35699240bc6f7740f5c7cbd78d9
https://findresearcher.sdu.dk:8443/ws/files/141556232/Comprehensive_characteristics_of_the_anticoagulant_activity_of_dabigatran_in_relation_to_its_plasma_concentration.pdf
https://findresearcher.sdu.dk:8443/ws/files/141556232/Comprehensive_characteristics_of_the_anticoagulant_activity_of_dabigatran_in_relation_to_its_plasma_concentration.pdf
Publikováno v:
Comuth, W J, Faaborg, L, Henriksen, L Ø & Münster, A-M B 2018, ' Measurement of dabigatran : previously demonstrated Hemoclot® Thrombin Inhibitor assay reagent instability on Sysmex CS-2100i is no longer an issue ', Scandinavian Journal of Clinical & Laboratory Investigation, vol. 78, no. 1-2, pp. 149-152 . https://doi.org/10.1080/00365513.2017.1403037
Comuth, W, Faaborg, L, Henriksen, L Ø & Münster, A-M B 2017, ' Measurement of dabigatran: previously demonstrated Hemoclot® Thrombin Inhibitor assay reagent instability on Sysmex CS-2100i is no longer an issue ', Scandinavian Journal of Clinical & Laboratory Investigation, vol. 78, no. 1-2, pp. 149-152 . https://doi.org/10.1080/00365513.2017.1403037
Comuth, W, Faaborg, L, Henriksen, L Ø & Münster, A-M B 2017, ' Measurement of dabigatran: previously demonstrated Hemoclot® Thrombin Inhibitor assay reagent instability on Sysmex CS-2100i is no longer an issue ', Scandinavian Journal of Clinical & Laboratory Investigation, vol. 78, no. 1-2, pp. 149-152 . https://doi.org/10.1080/00365513.2017.1403037
The Hemoclot® Thrombin Inhibitor (HTI) assay has been recommended for measurement of dabigatran concentrations in specific clinical situations. Traditionally, reagents for biochemical assays are prepared from instructions found in the package insert
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d15a5e64d88f8147b0ad9ede8d8c836
https://portal.findresearcher.sdu.dk/da/publications/1d5efdf6-baa0-46bf-8183-53bd182585f6
https://portal.findresearcher.sdu.dk/da/publications/1d5efdf6-baa0-46bf-8183-53bd182585f6
Autor:
Willemijn J. Comuth, Linda Ø Henriksen, Jerzy Malczynski, Anna-Marie Bloch Münster, Anne-Mette Haase, Daan van de Kerkhof
Publikováno v:
Comuth, W J, Haase, A-M, Henriksen, L Ø, Malczynski, J, van de Kerkhof, D & Münster, A-M B 2018, ' Cholestatic liver injury as a side-effect of dabigatran and the use of coagulation tests in dabigatran intoxication and after reversal by idarucizumab in bleeding and sepsis ', Scandinavian Journal of Clinical & Laboratory Investigation, vol. 78, no. 1-2, pp. 1-5 . https://doi.org/10.1080/00365513.2017.1402127
Scandinavian Journal of Clinical and Laboratory Investigation, 78(1-2), 1-5. Informa Healthcare
Scandinavian Journal of Clinical and Laboratory Investigation, 78(1-2), 1-5. Informa Healthcare
Idarucizumab, an antidote specific for dabigatran, became available recently. Dabigatran is not associated with increased risk of hepatotoxicity in comparison with warfarin, but it is seen as a rare side-effect. Cases of cholestatic liver injury due
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f2b7f57c45795baba2741ebf0aea37e
https://portal.findresearcher.sdu.dk/da/publications/5c745c7b-e3cb-4a53-b5ff-21fb4d36e8e2
https://portal.findresearcher.sdu.dk/da/publications/5c745c7b-e3cb-4a53-b5ff-21fb4d36e8e2
Publikováno v:
Scandinavian journal of clinical and laboratory investigation. 78(1-2)
The Hemoclot
Publikováno v:
Drug Safety, 39, 1, pp. 5-13
Drug Safety, 39, 5-13
Husted, S, Verheugt, F & Comuth, W 2015, ' Reversal Strategies for NOACs : State of Development, Possible Clinical Applications and Future Perspectives ', Drug Safety . https://doi.org/10.1007/s40264-015-0357-x
Drug Safety, 39, 5-13
Husted, S, Verheugt, F & Comuth, W 2015, ' Reversal Strategies for NOACs : State of Development, Possible Clinical Applications and Future Perspectives ', Drug Safety . https://doi.org/10.1007/s40264-015-0357-x
Contains fulltext : 171421.pdf (Publisher’s version ) (Closed access) The non-vitamin K antagonist oral anticoagulants (NOACs) are used for thromboembolic prophylaxis of patients with atrial fibrillation and in the treatment as well as secondary pr